Pepsi Shrinks Portions to Target GLP-1 Market

PepsiCo is adapting to evolving consumer preferences driven by the increasing use of GLP-1 weight-loss medications. The company is introducing smaller portion sizes and lower-calorie alternatives to align with a market where consumers are reportedly eating and drinking less.

PepsiCo CEO Ramon Laguarta has stated that the widespread adoption of GLP-1 drugs is altering consumer behavior, leading to a demand for "more hydration, more fiber in their diets, more protein and the fact that they want to stay in their little pleasures, and with smaller portions." The company's 100 and 120-calorie packs have performed well, alongside a recently launched 30-calorie prebiotic soda.

This strategic shift comes at a time when PepsiCo faces mixed financial results, with North American beverage volume declining. Factors like tightening consumer budgets and inflation have impacted sales, particularly in convenience stores and gas stations, according to company executives.

Industry analysts offer varying perspectives on the strategy. Katherine Machado O’Hara, with extensive experience in consumer goods, views smaller portion options as a pragmatic first step to maintain brand loyalty. However, registered dietitian Ashley Koff critically suggests that this approach may be more of a marketing tactic than a genuine solution for individuals managing their weight with GLP-1 medications.